Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 6/20 | 0.39 |
| ▸ | CDK2 | P24941 | 6/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.39 |
| ▸ | AURKA | O14965 | 5/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946526 | 0.88 | KDM4E (0.41) | CCNA2CDK2CCNA1AURKABRD4 | |
| SCHEMBL4949121 | 0.76 | AURKA (0.62) | CCNA2CDK2CCNA1AURKAHCAR2 | |
| SCHEMBL4948583 | 0.70 | LMNA (0.32) | — | |
| SCHEMBL4943590 | 0.65 | AURKA (0.58) | AURKAHCAR2KMT2A | |
| SCHEMBL8751588 | 0.65 | TSHR (0.52) | KMT2A | |
| SCHEMBL4949038 | 0.64 | HCAR2 (0.47) | HCAR2CREBBPKMT2A | |
| SCHEMBL17222996 | 0.64 | HCAR2 (0.43) | HCAR2KMT2A | |
| SCHEMBL4946521 | 0.64 | AURKA (0.58) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL27320089 | 0.62 | TSHR (0.47) | KMT2A | |
| SCHEMBL13374012 | 0.62 | CREBBP (0.57) | HCAR2BRD4CREBBPMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| EP-1885725-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | CCNA2 990/4885CDK2 534/4885CCNA1 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.